 |
|
|
UPDATED: Tue, 03/18/2008 - 12:20pm
Ninth Eilat Conference on New Antiepileptic Drugs (Eilat IX) / June 15 - 19, 2008
Sponsored by:
 The Hebrew University of Jerusalem, Israel |
 Epilepsy Therapy Project |
Scheduled for June 15 – 19th in Sitges, Spain, the Eilat Conferences on New Antiepileptic Drugs (AEDs) is designed to provide an in-depth progress report on new antiepileptic drugs in different stages of development, as well as to present new findings on second-generation treatments. In addition, sessions will be devoted to:
- Old and New AEDs in Generalized Epilepsies
- Novel Formulations and Routes of Administration of AEDs
- Common Targets and Mechanisms of Action of Drugs for the Treatment of Epilepsy and other CNS disorders
- Perspectives on new AED discovery
Registration
- To Register by AIRMAIL or FAX, click here.
- For additional information about registration, please visit: General Information
Program
SATELLITE SYMPOSIUM
All registered participants of the Ninth Eilat Conference on New Antiepileptic Drugs (EILAT IX) are invited to participate in the Satellite Symposium which will be held at the Melia Sitges, the Conference Venue. Participation is on a "first come first served basis". Kindly mark your intention to participate on the enclosed Registration Form.
SUNDAY, JUNE 15, 2008 |
|
| 16:30 - 18:30 | CARISBAMATE : Johnson & Johnson Satellite Symposium |
|
|
| 08:00 – 08:30 | Opening Session : OPENING REMARKS AND GREETINGS |
|
|
|
| Session I 08:30 – 13:00 |
OLD AND NEW AEDs IN GENERALIZED EPILEPSIES | Chairpersons: E. Abadie (France), R. Katz (USA) |
| 08:30 | GENERALIZED EPILEPSIES: CLASSIFICATION, EPIDEMIOLOGY AND UNMET NEEDS | R. Guerrini (Italy) |
| 08:50 | Discussion |
| 09:00 | PREDICTING EFFICACY OF AEDs IN GENERALIZED EPILEPSIES | H.S. White (USA) |
| 09:20 | Discussion |
| Session I 08:30 – 13:00 |
CLINICAL TRIALS OF NEW AEDs IN GENERALIZED EPILEPSIES: TOO LITTLE, TOO LATE? DIFFERENCES IN PERSPECTIVES |
| 09:30 | Syndromes with onset in Early Childhood | O. Dulac (France) |
| 09:50 | Discussion |
| 10:00 | Syndromes with onset in Adolescence and Adults | K. Eriksson (Finland) |
| 10:20 | Discussion |
| 10:30 | Coffee |
| 11:00 | The Regulator | R. Katz (USA) |
| 11:20 | Discussion |
| 11:30 | The Pharmaceutical Industry | P. Verdru (Belgium) |
| 11:50 | Discussion |
| 12:00 | ORPHAN DRUGS FOR RARE SYNDROMES | C. Chiron (France) |
| 12:20 | Discussion |
| 12:30 | OLD AND NEW AEDs IN THE TREATMENT OF IDIOPATHIC GENERALIZED EPILEPSIES: REVIEW OF THE EVIDENCE AND PLACE IN THE TREATMENT ALGORITHM | P.H. Ryvlin (France) |
| 12:50 | Discussion |
| 13:00 | Coffee |
|
|
|
| Session II 13:30 – 15:00 |
NOVEL FORMULATIONS AND ROUTES OF ADMINISTRATION OF AEDs: INNOVATION | Chairpersons: S. Johannessen (Norway), P. Wolf (Denmark) |
| 13:30 | MODIFIED RELEASE FORMULATIONS OF AEDs: REAL PROGRESS OR MARKETING GIMMICK? | E. Trinka (Austria) |
| 13:50 | Discussion |
| 14:00 | Debate: SHOULD WE AVOID THE USE OF GENERIC PRODUCTS OF AEDs? | Pro: T.A. Pedley (USA) - Con: E. Perucca (Italy) |
| 14:20 | Discussion |
| 14:30 | WHAT IS THE BEST FOR EMERGENCY TREATMENT WHEN THE I.V. ROUTE IS NOT AVAILABLE? | J.C. Cloyd (USA) |
| 14:50 | Discussion |
|
|
| Session III - A 08:00 – 10:00 |
DRUGS IN DEVELOPMENT | Chairpersons: M. Bialer (Israel), R.H. Levy (USA) |
| 08:00 | BRIVARACETAM (ucb 34714) | P. von Rosenstiel, UCB S.A., (Belgium) |
| 08:20 | Discussion |
| 08:30 | CARISBAMATE (RWJ-333369) | G.P. Novak, Johnson &Johnson Pharmaceutical Research & Development (USA) |
| 08:50 | Discussion |
| 09:00 | 2-DEOXY-GLUCOSE | Presented by T.P. Sutula, University of Wisconsin (USA) |
| 09:20 | Discussion |
| 09:30 | ESLICARBAZEPINE ACETATE (BIA 2-093) | BIAL - Portela & Cª., S.A. (Portugal), presented by E. Ben Menachem, University of Goteborg (Sweden) |
| 09:50 | Discussion |
| 10:00 | Coffee |
| 10:30 – 12:30 | DRUGS IN DEVELOPMENT | Chairpersons: E. Perucca (Italy), H.S. White (USA) |
| 10:30 | FLUOROFELBAMATE | B.A. Roecklein, MedPointe Pharmaceuticals (USA) |
| 10:50 | Discussion |
| 11:00 | GANAXOLONE | V. Pieribone, Marinus Pharmaceuticals (USA) |
| 11:20 | Discussion |
| 11:30 | HUPERZINE | Presented by S. Schachter, Harvard Medical School (USA) |
| 11:50 | Discussion |
|
|
|
| Session III - B 10:30 – 12:30 |
DRUGS IN DEVELOPMENT |
| 12:00 | LACOSAMIDE (SPM 927) | T. Sullivan, Schwarz BioSciences (USA) |
| 12:20 | Discussion |
| 12:30 | Lunch |
|
|
|
| Session III - C 14:00 – 15:30 |
DRUGS IN DEVELOPMENT | Chairpersons: S.I. Johannessen (Norway), H.J. Kupferberg (USA) |
| 14:00 | NAX 5055 | NeuroAdjuvants (USA), presented by G. Bulaj, University of Utah (USA) |
| 14:20 | Discussion |
| 14:30 | RETIGABINE | H. Mansbach, Valeant Pharmaceuticals (USA) |
| 14:50 | Discussion |
| 15:00 | SELETRACETAM (ucb 44212) | B. Bennet, UCB Pharma (USA) |
| 15:20 | Discussion |
| 15:30 | Coffee |
|
|
|
| Session III - D 16:00 – 19:30 |
DRUGS IN DEVELOPMENT | Chairpersons: B. Schmidt (Germany), T. Tomson (Sweden) |
| 16:00 | T2000 | Presented by M. Gasior, Cephalon, Inc. (USA) |
| 16:20 | Discussion |
| 16:30 | TONABERSAT | P. Blower, Minster Pharmaceuticals plc (UK) |
| 16:50 | Discussion |
| 17:00 | VALROCEMIDE | Presented by M. Bialer, The Hebrew University of Jerusalem (Israel) |
| 17:20 | Discussion |
| 17:30 | JZP-4 | M. Foreman, Jazz Pharmaceuticals, (USA) |
| 17:50 | Discussion |
| 18:00 | PROPYLISOPROPYL ACETAMIDE (PID) | Jazz Pharmaceuticals (USA), presented by M. Bialer, The Hebrew University of Jerusalem (Israel) |
| 18:20 | Discussion |
| 18:30 | VALNOCTAMIDE STEREOSOMERS | Presented by R.H. Farber, Neurocrine Biosciences (USA), and |
| 18:50 | Discussion |
| 19:00 | YKP3089 | S.J. Lee, SK Life Science, New Jersey (USA) |
| 19:20 | Discussion |
|
|
| Session IV - A 08:00 – 10:30 |
PROGRESS REPORT ON SECOND-GENERATION TREATMENTS | Chairpersons: I. Leppik (USA), M. Neufeld (Israel) |
| 08:00 | FELBAMATE | B.A. Roecklein, MedPointe Pharmaceuticals (USA) |
| 08:20 | Discussion |
| 08:30 | GABAPENTIN | Presented by B. Schmidt, Wittnau (Germany) |
| 08:50 | Discussion |
| 09:00 | LAMOTRIGINE | Presented by F.M.C. Besag, Twinwoods Health Resource Centre Bedfordshire & Luton Institutes of Psychiatry and Child Health (UK) |
| 09:20 | Discussion |
| 09:30 | LEVETIRACETAM | F. Tonner, UCB S.A. (Belgium) |
| 09:50 | Discussion |
| 10:00 | OXCARBAZEPINE | Presented by C. Elger, University of Bonn (Germany) |
| 10:20 | Discussion |
| 10:30 | Coffee |
|
|
|
| Session IV - B 11:00 – 13:30 |
PROGRESS REPORT ON SECOND-GENERATION TREATMENTS | Chairpersons: M. Baulac (France), P.H. Ryvlin (France) |
| 11:00 | PREGABALIN | Pfizer Inc. USA, presented by B. Uthman, University of Florida and McKnight Brain Insitute (USA) |
| 11:20 | Discussion |
| 11:30 | RUFINAMIDE | A. Yeates, Eisai Europe Ltd (UK) |
| 12:00 | STIRIPENTOL | Presented by C. Chiron, Necker-Enfants Malades Hospital, Paris (France) |
| 12:20 | Discussion |
| 12:30 | TIAGABINE | Presented by R. Kälviäinen, Kuopio University Hospital (Finland) |
| 12:50 | Discussion |
| 13:00 | TOPIRAMATE | S. Ness, Johnson & Johnson Pharmaceutical Research & Development (USA) |
| 13:20 | Discussion |
| 13:30 | Lunch Break |
|
|
|
| Session IV - C 14:30 – 17:00 |
PROGRESS REPORT ON SECOND-GENERATION TREATMENTS | Chairpersons: C.E. Elger (Germany), S. Shorvon (UK) |
| 14:30 | VIGABATRIN | S. Collins, Ovation Pharmaceuticals, Inc (USA) |
| 14:50 | Discussions |
| 15:00 | ZONISAMIDE | R. van Maanen, Eisai Ltd (EGC) (UK) |
| 15:20 | Discussions |
| 15:30 | OXCARBAZEPINE MODIFIED-RELEASE (MR) FORMULATION | Desitin Arzneimittel GmbH (Germany), presented by B.J. Steinhoff, Epilepsy Center Kork (Germany) |
| 15:50 | Discussion |
| 16:00 | VALPROIC ACID (DIVALPROEX SODIUM) EXTENDED-RELEASE (ER) FORMULATION | R.C. Reed, Abbott Laboratories (USA) |
| 16:20 | Discussion |
| 16:30 | LAMOTRIGINE EXTENDED RELEASE (ER) FORMULATION | K. Vanlandingham, GlaxoSmithKline (USA) |
| 16:50 | Discussions |
|
|
| Session V 08:30 – 12:00 |
COMMON TARGETS AND MECHANISMS OF ACTION OF DRUGS FOR THE TREATMENT OF EPILEPSY AND OTHER CNS DISORDERS: IS THERE AN OVERLAP? | Chairpersons: E. Perucca (Italy), T. Tomson (Sweden) |
| 08:30 | EPILEPSY AND NEUROPATHIC PAIN | M. Devor (Israel) |
| 08:50 | Discussion |
| 09:00 | EPILEPSY AND BIPOLAR DISORDERS | A. Harwood (UK) |
| 09:20 | Discussion |
| 09:30 | EPILEPSY AND MIGRAINE | M.A. Rogawski (USA) |
| 09:50 | Discussion |
| 10:00 | Coffee |
| 10:30 | EPILEPSY AND ADDITIONAL CNS DISORDERS | S. Shorvon (UK) |
| 10:50 | Discussion |
| 11:00 | THE UTILIZATION OF AEDs IN NON-EPILEPTIC CNS DISORDERS-CLINICAL PERSPECTIVES | A.M. Kanner (USA) |
| 11:20 | Discussion |
| 11:30 | TOWARDS A BETTER UNDERSTANDING OF AED SITES OF ACTION: IMAGING EVALUATION OF ANTIEPILEPTIC DRUGS | W.H. Theodore (USA) |
| 11:50 | Discussion |
|
|
|
| Session VI 12:00 – 14:00 |
OPPORTUNITIES AND PERSPECTIVES IN NEW AED DISCOVERY | Chairpersons: R. Twyman (USA), H.S. White (USA) |
| 12:00 | CREATING OPPORTUNITIES TO FUND NEW THERAPIES FOR EPILEPSY | J. Cramer, Epilepsy Therapy Development Project (USA) |
| 12:20 | Discussion |
| 12:30 | CURRENT PERSPECTIVES IN NEW AED DISCOVERY | PANEL DISCUSSION
|
| 14:00 | Closing Remarks | S.I. Johannessen (Norway) |
| 16:00 – 20:00 | Satellite Symposium - CEA-SPONSORED SYMPOSIUM ON EMEA GUIDELINES FOR NEW AEDs | Chairpersons: E. Abadie (France), M. Baulac (France) |
Organizing Committee:
- Meir Bialer, Jerusalem, Israel
- Svein I. Johannessen, Sandvika, Norway
- Rene H. Levy, Seattle USA
- Emilio Perucca, Pavia, Italy
- Torbjörn Tomson, Stockholm, Sweden
- H. Steven White, Salt Lake City, USA
Travel and Accommodations
Target Conferences is the official travel agent for the Ninth Eilat Conference on New Antiepileptic Drugs and will be offering special reduced rates for accommodation and conference tours.
Target Conferences Ltd.
PO Box 29041, Tel Aviv 61290, Israel
Tel: +972 3 5175150, Fax +972 3 5175155
E-mail: eilatix@targetconf.com
For more travel information, including hotel, air travel and transportation to/from conference venue: click here.
Conference Secretariat
If you require any additional information or assistance, please contact the Secretariat:
Ninth Eilat Conference on New Antiepileptic Drugs (Eilat IX)
PO Box 29041, Tel Aviv 61290, Israel
Tel: +972 3 5175150, Fax: +972 3 5175155
e-mail: eilatix@targetconf.com
To view detailed conference information, please visit: www.Eilat-aeds.com